ClinicalTrials.gg
Not yet recruitingNCT07849920Updated Oct 16, 2026

Walk Together Efficacy Trial

An interventional study of Walk Together and Hypertension education in Hypertension, sponsored by University of Texas Southwestern Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Oct 16, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Hypertension by University of Texas Southwestern Medical Center — 7 open to participants now, 7 under way, none of them phase 3. Hypertension · University of Texas Southwestern Medical Center.

Planned enrollment
6th of 27
400 · median 85
Started
2027
the only one that year
No phase
11 of 31
4 open now
Registered
31st of 31
by date

Among the 31 studies in Hypertension by University of Texas Southwestern Medical Center, this one is the 6th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2027, is one of 11 with no phase, and was the 31st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

7 of the 31 studies in Hypertension by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Hypertension by University of Texas Southwestern Medical Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the Walk Together family-based intervention can improve hypertension self-management and blood pressure control in Black and African American primary care patients living with uncontrolled hypertension. The main questions it aims to answer are:

  • Do patients and family members who complete Walk Together take better care of their health?
  • Does Walk Together lower blood pressure? Researchers will compare the Walk Together intervention to a hypertension education intervention to see if Walk Together works to improve blood pressure.

Participants will:

  • Complete four study sessions over 7 to 10 weeks
  • Measure their blood pressure at home
  • Answer questions about their family and their health 6 times over 8 months
Read the detailed description

Hypertension is the most significant risk factor for racial disparities in mortality and life expectancy. African Americans, in particular, are at greater risk of developing hypertension earlier and experiencing worse hypertension-related outcomes. Hypertension is also a modifiable risk factor for cardiovascular disease, in part via self-management behavior which is critical for achieving hypertension control. Black and African American individuals often report difficulties with self-management adherence due in part to challenges in sustaining necessary lifestyle changes, and environmental barriers to engaging in self-care. African Americans also frequently report family emotional and behavioral support is critical for achieving self-management goals, while shared health behaviors, insufficient support, and family stress are often identified as barriers to self-management. Yet, family support has remained an untapped resource in hypertension self-management interventions. This study will test the efficacy of a new family-based hypertension self-management intervention which was designed and adapted with and for Black and African American primary care patients living with uncontrolled hypertension and their family support persons via prior community-based participatory research. The intervention -- Walk Together -- includes four dyadic (i.e., patient plus family support person) sessions over approximately eight weeks with the goal of optimizing family relationship quality including family support for hypertension self-management, plus improving hypertension knowledge, while addressing common barriers to hypertension management via referrals to standard of care resources, health information technology, and integration into patients' primary care clinics. Using a randomized controlled trial design, the investigators will (1) identify the extent to which the Walk Together intervention increases hypertension self-management adherence and improves blood pressure control compared to a hypertension education control condition (HypEd); (2) examine family support (i.e., patient-family support person relationship quality, and family support for hypertension management behaviors) and hypertension knowledge as mechanisms of effect through which Walk Together leads to improvements in self-management adherence and blood pressure control outcomes; and, (3) evaluate the family-level positive health impacts of the Walk Together intervention on participating family support persons' hypertension knowledge and health behaviors.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Family support
  • Integrated health care systems
  • Healthy lifestyle
  • Hypertension
  • Community-based participatory research
  • Primary care
  • African American
  • Blood pressure
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Black or African American
  • Age 18 to 75
  • Diagnosis of essential hypertension
  • Two clinic-based blood pressure values ≥ 130/ ≥ 80 in 12 months prior
  • Available family support person to join the study who agrees to participate
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of hypertension is made exclusively during pregnancy
  • Documented cognitive impairment in patient's medical record
  • Presence of severe psychiatric condition (i.e., current psychotic disorder or suicidality)
  • Diagnosis of sustained atrial fibrillation
  • Past-year myocardial infarction
  • Diagnosis of chronic kidney disease ( \<20)
  • (other than non-melanoma skin cancer) in past 2 years
  • Prior organ transplant
  • Prior participation in earlier Walk Together studies
  • Participation in prior hypertension health education intervention
  • Family support person is under the age of 18 or over age of 25
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Walk Together

    Walk Together incudes four dyadic sessions, integrated into patients' primary care, to improve hypertension self-management adherence and blood pressure control via optimizing family relationship quality and increasing hypertension knowledge.

    Behavioral: Walk Together

  • Sham comparator
    Hypertension Education (HypEd)

    Hypertension education control condition includes four points of contact providing hypertension education and follow-up regarding hypertension self-management.

    Behavioral: Hypertension education

Interventions

  • BehavioralWalk Together

    Walk Together incudes four sessions delivered in patients' primary care clinics (in-person or via telehealth) over approximately eight weeks. Sessions are dyadic (i.e., all sessions include the patient participant plus the patient's self-identified family support person), last approximately 4 hours total (ranging from 30-90 minutes each), and are facilitated by a trained behavioral interventionist with expertise in couples and family therapy. The goals of the intervention are to (a) improve family relationship quality (i.e., dyadic relationship quality and family support for hypertension self-management) and (b) improve hypertension knowledge, in order to improve hypertension self-management adherence and improve blood pressure control. All participants are provided a blood pressure monitor for remote monitoring. Environmental barriers to self-management adherence are also addressed consistent with standard care.

  • BehavioralHypertension education

    HypEd includes four points of contact including one dyadic (i.e., patient participants plus patient-identified family support persons) baseline session (30 minutes) that includes education on use of study-provided blood pressure monitors and accurate blood pressure monitoring, hypertension basics, and hypertension self-management goal-setting. All dyads will receive a copy of National Heart Lung and Blood Institute's "On the Move to Better Heart Health for African Americans" educational booklet. Patients will then receive a phone call to check-in regarding progress in their hypertension management goal and reviewing the educational booklet at 1-2 weeks, 3-4 weeks, and 7-10 weeks. All participants will receive a blood pressure monitor for remote monitoring.

06

What researchers measure

Primary outcomes

  1. Hypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Patients' hypertension self-management adherence will be measured by the Hypertension Self-Care Activity Level Effects (H-SCALE), a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6. Higher scores indicate greater adherence.

    Time frame: Baseline

  2. Hypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Patients' hypertension self-management adherence will be measured by the Hypertension Self-Care Activity Level Effects (H-SCALE), a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6. Higher scores indicate greater adherence.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  3. Hypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Patients' hypertension self-management adherence will be measured by the Hypertension Self-Care Activity Level Effects (H-SCALE), a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6. Higher scores indicate greater adherence.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  4. Hypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Patients' hypertension self-management adherence will be measured by the Hypertension Self-Care Activity Level Effects (H-SCALE), a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6. Higher scores indicate greater adherence.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  5. Hypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Patients' hypertension self-management adherence will be measured by the Hypertension Self-Care Activity Level Effects (H-SCALE), a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6. Higher scores indicate greater adherence.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  6. Hypertension self-management behavior adherence as measured by blood pressure monitor use adherence

    Hypertension self-management adherence will be, in part, assessed via adherence to blood pressure monitor (BPM) use calculated as (a) the ratio of days patient participants use their study-provided BPM to days enrolled in the study and (b) dichotomizing BPM use at greater than or equal to 70% versus less than 70% of enrolled days

    Time frame: Baseline

  7. Hypertension self-management behavior adherence as measured by blood pressure monitor use adherence

    Hypertension self-management adherence will be, in part, assessed via adherence to blood pressure monitor (BPM) use calculated as (a) the ratio of days patient participants use their study-provided BPM to days enrolled in the study and (b) dichotomizing BPM use at greater than or equal to 70% versus less than 70% of enrolled days

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  8. Hypertension self-management behavior adherence as measured by blood pressure monitor use adherence

    Hypertension self-management adherence will be, in part, assessed via adherence to blood pressure monitor (BPM) use calculated as (a) the ratio of days patient participants use their study-provided BPM to days enrolled in the study and (b) dichotomizing BPM use at greater than or equal to 70% versus less than 70% of enrolled days

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  9. Hypertension self-management behavior adherence as measured by blood pressure monitor use adherence

    Hypertension self-management adherence will be, in part, assessed via adherence to blood pressure monitor (BPM) use calculated as (a) the ratio of days patient participants use their study-provided BPM to days enrolled in the study and (b) dichotomizing BPM use at greater than or equal to 70% versus less than 70% of enrolled days

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  10. Hypertension self-management behavior adherence as measured by blood pressure monitor use adherence

    Hypertension self-management adherence will be, in part, assessed via adherence to blood pressure monitor (BPM) use calculated as (a) the ratio of days patient participants use their study-provided BPM to days enrolled in the study and (b) dichotomizing BPM use at greater than or equal to 70% versus less than 70% of enrolled days

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  11. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. All three measurements, and the last two measurements, will be averaged at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used). Blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) will be assessed using an average of readings completed within 7 days of the primary outcome timeframe.

    Time frame: Baseline

  12. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. All three measurements, and the last two measurements, will be averaged at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used). Blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) will be assessed using an average of readings completed within 7 days of the primary outcome timeframe.

    Time frame: 1 month (readings completed within 7 days of session 3)

  13. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. All three measurements, and the last two measurements, will be averaged at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used). Blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) will be assessed using an average of readings completed within 7 days of the primary outcome timeframe.

    Time frame: 2 months (readings completed within 7 days of session 4)

  14. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. All three measurements, and the last two measurements, will be averaged at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used). Blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) will be assessed using an average of readings completed within 7 days of the primary outcome timeframe.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline, using 7-day averages)

  15. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. All three measurements, and the last two measurements, will be averaged at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used). Blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) will be assessed using an average of readings completed within 7 days of the primary outcome timeframe.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline, using 7-day averages)

  16. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. All three measurements, and the last two measurements, will be averaged at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used). Blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) will be assessed using an average of readings completed across 30 days (1 month) of the primary outcome timeframe.

    Time frame: Baseline

  17. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. All three measurements, and the last two measurements, will be averaged at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used). Blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) will be assessed using an average of readings completed across 30 days (1 month) of the primary outcome timeframe.

    Time frame: Month 1

  18. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. All three measurements, and the last two measurements, will be averaged at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used). Blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) will be assessed using an average of readings completed across 30 days (1 month) of the primary outcome timeframe.

    Time frame: Month 2

  19. Blood pressure control

    Patients will be asked to complete three consecutive measurements, once daily, in the morning. All three measurements, and the last two measurements, will be averaged at each distinct measurement timepoint (i.e., each day the study-provided blood pressure monitor is used). Blood pressure (BP) control (indicated by systolic BP less than or equal to 130 and/or diastolic BP less than or equal to 80) will be assessed using an average of readings completed across 30 days (1 month) of the primary outcome timeframe.

    Time frame: Month 7

Secondary outcomes

  1. Dyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index

    Dyadic (i.e., patient-family support person) relationship satisfaction is measured by the Relationship Satisfaction Index (adapted for this study from the Couples Satisfaction Index). Possible scores range from 0 to 21, where higher scores mean greater satisfaction.

    Time frame: Baseline

  2. Dyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index

    Dyadic (i.e., patient-family support person) relationship satisfaction is measured by the Relationship Satisfaction Index (adapted for this study from the Couples Satisfaction Index). Possible scores range from 0 to 21, where higher scores mean greater satisfaction.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  3. Dyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index

    Dyadic (i.e., patient-family support person) relationship satisfaction is measured by the Relationship Satisfaction Index (adapted for this study from the Couples Satisfaction Index). Possible scores range from 0 to 21, where higher scores mean greater satisfaction.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  4. Dyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index

    Dyadic (i.e., patient-family support person) relationship satisfaction is measured by the Relationship Satisfaction Index (adapted for this study from the Couples Satisfaction Index). Possible scores range from 0 to 21, where higher scores mean greater satisfaction.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  5. Dyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index

    Dyadic (i.e., patient-family support person) relationship satisfaction is measured by the Relationship Satisfaction Index (adapted for this study from the Couples Satisfaction Index). Possible scores range from 0 to 21, where higher scores mean greater satisfaction.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  6. Family relationship quality as measured by the FACES-IV Short Form

    Family relationship quality (broadly, in family relationships specified by the participant) is measured by the 24-item, 8-subscale Family Adaptability and Cohesion Scale IV - Short Form (FACES IV-SF). Possible scores range from 3-15 for each subscale where higher scores indicate higher levels of the subscale's dimension.

    Time frame: Baseline

  7. Family relationship quality as measured by the FACES-IV Short Form

    Family relationship quality (broadly, in family relationships specified by the participant) is measured by the 24-item, 8-subscale Family Adaptability and Cohesion Scale IV - Short Form (FACES IV-SF). Possible scores range from 3-15 for each subscale where higher scores indicate higher levels of the subscale's dimension.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  8. Family relationship quality as measured by the FACES-IV Short Form

    Family relationship quality (broadly, in family relationships specified by the participant) is measured by the 24-item, 8-subscale Family Adaptability and Cohesion Scale IV - Short Form (FACES IV-SF). Possible scores range from 3-15 for each subscale where higher scores indicate higher levels of the subscale's dimension.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  9. Family relationship quality as measured by the FACES-IV Short Form

    Family relationship quality (broadly, in family relationships specified by the participant) is measured by the 24-item, 8-subscale Family Adaptability and Cohesion Scale IV - Short Form (FACES IV-SF). Possible scores range from 3-15 for each subscale where higher scores indicate higher levels of the subscale's dimension.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  10. Family relationship quality as measured by the FACES-IV Short Form

    Family relationship quality (broadly, in family relationships specified by the participant) is measured by the 24-item, 8-subscale Family Adaptability and Cohesion Scale IV - Short Form (FACES IV-SF). Possible scores range from 3-15 for each subscale where higher scores indicate higher levels of the subscale's dimension.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  11. Family support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey

    Family support for hypertension management is measured by the family and friends subscale of the Chronic Illness Resources Survey. Possible scores range from 1-5, where higher scores indicate greater support.

    Time frame: Baseline

  12. Family support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey

    Family support for hypertension management is measured by the family and friends subscale of the Chronic Illness Resources Survey. Possible scores range from 1-5, where higher scores indicate greater support.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  13. Family support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey

    Family support for hypertension management is measured by the family and friends subscale of the Chronic Illness Resources Survey. Possible scores range from 1-5, where higher scores indicate greater support.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  14. Family support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey

    Family support for hypertension management is measured by the family and friends subscale of the Chronic Illness Resources Survey. Possible scores range from 1-5, where higher scores indicate greater support.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  15. Family support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey

    Family support for hypertension management is measured by the family and friends subscale of the Chronic Illness Resources Survey. Possible scores range from 1-5, where higher scores indicate greater support.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  16. Hypertension knowledge as measured by the HTN Evaluation of Lifestyle and Management Knowledge Scale

    Patients' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Baseline

  17. Hypertension knowledge as measured by the HTN Evaluation of Lifestyle and Management Knowledge Scale

    Patients' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  18. Hypertension knowledge as measured by the HTN Evaluation of Lifestyle and Management Knowledge Scale

    Patients' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  19. Hypertension knowledge as measured by the HTN Evaluation of Lifestyle and Management Knowledge Scale

    Patients' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  20. Hypertension knowledge as measured by the HTN Evaluation of Lifestyle and Management Knowledge Scale

    Patients' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

Other outcomes

  1. Hypertension knowledge as measured by the Hypertension Evaluation of Lifestyle and Management Knowledge Scale

    Family support persons' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Baseline

  2. Hypertension knowledge as measured by the Hypertension Evaluation of Lifestyle and Management Knowledge Scale

    Family support persons' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Following session 3 (approx. 3 weeks after Baseline)

  3. Hypertension knowledge as measured by the Hypertension Evaluation of Lifestyle and Management Knowledge Scale

    Family support persons' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  4. Hypertension knowledge as measured by the Hypertension Evaluation of Lifestyle and Management Knowledge Scale

    Family support persons' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  5. Hypertension knowledge as measured by the Hypertension Evaluation of Lifestyle and Management Knowledge Scale

    Family support persons' knowledge of hypertension facts will be assessed via the Hypertension Evaluation of Lifestyle and Management Knowledge Scale. Possible scores range from 0 to 13 with higher scores indicating greater knowledge.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  6. Health behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Health behaviors reflecting hypertension self-management adherence for family support persons living with hypertension will be measured by the Hypertension Self-Care Activity Level Effects (H-SCALE) a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6. Higher scores indicate greater adherence.

    Time frame: Baseline

  7. Health behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Health behaviors reflecting hypertension self-management adherence for family support persons living with hypertension will be measured by the Hypertension Self-Care Activity Level Effects (H-SCALE), a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6. Higher scores indicate greater adherence.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  8. Health behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Health behaviors reflecting hypertension self-management adherence for family support persons living with hypertension will be measured by the Hypertension Self-Care Activity Level Effects (H-SCALE), a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6. Higher scores indicate greater adherence.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  9. Health behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Health behaviors reflecting hypertension self-management adherence for family support persons living with hypertension will be measured by the Hypertension Self-Care Activity Level Effects (H-SCALE), a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6. Higher scores indicate greater adherence.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  10. Health behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)

    Health behaviors reflecting hypertension self-management adherence for family support persons living with hypertension will be measured by the Hypertension Self-Care Activity Level Effects (H-SCALE), a self-report scale with that assesses adherence to hypertension medications, physical activity, healthy (DASH) diet, alcohol intake, tobacco exposure, and weight management recommendations across 6 subscales using (a) continuous subscale scores, (b) validated dichotomized cutoffs to indicate adherence within each subscale, and (c) an overall adherence index measuring cumulative adherence, ranging from 0 to 6. Higher scores indicate greater adherence.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  11. Health behavior as measured by the PhenX smoking status protocol

    Family support persons' health behavior will be measured in part by the PhenX cigarette smoking status protocol which assesses current, past-year, and historical smoking status.

    Time frame: Baseline

  12. Health behavior as measured by the PhenX smoking status protocol

    Family support persons' health behavior will be measured in part by the PhenX cigarette smoking status protocol which assesses current, past-year, and historical smoking status.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  13. Health behavior as measured by the PhenX smoking status protocol

    Family support persons' health behavior will be measured in part by the PhenX cigarette smoking status protocol which assesses current, past-year, and historical smoking status.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  14. Health behavior as measured by the PhenX smoking status protocol

    Family support persons' health behavior will be measured in part by the PhenX cigarette smoking status protocol which assesses current, past-year, and historical smoking status.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  15. Health behavior as measured by the PhenX smoking status protocol

    Family support persons' health behavior will be measured in part by the PhenX cigarette smoking status protocol which assesses current, past-year, and historical smoking status.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  16. Health behavior as measured by the PhenX alcohol use protocol

    Family support persons' health behavior will be measured in part by the PhenX alcohol 30-day quantity and frequency protocol questionnaire which assesses lifetime and past-month use of alcohol, where higher values mean greater alcohol use.

    Time frame: Baseline

  17. Health behavior as measured by the PhenX alcohol use protocol

    Family support persons' health behavior will be measured in part by the PhenX alcohol 30-day quantity and frequency protocol questionnaire which assesses lifetime and past-month use of alcohol, where higher values mean greater alcohol use.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  18. Health behavior as measured by the PhenX alcohol use protocol

    Family support persons' health behavior will be measured in part by the PhenX alcohol 30-day quantity and frequency protocol questionnaire which assesses lifetime and past-month use of alcohol, where higher values mean greater alcohol use.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  19. Health behavior as measured by the PhenX alcohol use protocol

    Family support persons' health behavior will be measured in part by the PhenX alcohol 30-day quantity and frequency protocol questionnaire which assesses lifetime and past-month use of alcohol, where higher values mean greater alcohol use.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  20. Health behavior as measured by the PhenX alcohol use protocol

    Family support persons' health behavior will be measured in part by the PhenX alcohol 30-day quantity and frequency protocol questionnaire which assesses lifetime and past-month use of alcohol, where higher values mean greater alcohol use.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  21. Health behavior as measured by the PhenX dietary intake protocol

    Family support persons' health behavior will be measured in part by the PhenX dietary intake protocol questionnaire which assesses past-month frequency of intake of various food items.

    Time frame: Baseline

  22. Health behavior as measured by the PhenX dietary intake protocol

    Family support persons' health behavior will be measured in part by the PhenX dietary intake protocol questionnaire which assesses past-month frequency of intake of various food items.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  23. Health behavior as measured by the PhenX dietary intake protocol

    Family support persons' health behavior will be measured in part by the PhenX dietary intake protocol questionnaire which assesses past-month frequency of intake of various food items.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  24. Health behavior as measured by the PhenX dietary intake protocol

    Family support persons' health behavior will be measured in part by the PhenX dietary intake protocol questionnaire which assesses past-month frequency of intake of various food items.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  25. Health behavior as measured by the PhenX dietary intake protocol

    Family support persons' health behavior will be measured in part by the PhenX dietary intake protocol questionnaire which assesses past-month frequency of intake of various food items.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  26. Health behavior as measured by the PhenX physical activity protocol

    Family support persons' health behavior will be measured in part by the PhenX comprehensive adult physical activity protocol questionnaire which assesses past-year frequency of physical activity. Scores range from 1 to 10 where higher scores indicate more intense usual physical activity.

    Time frame: Baseline

  27. Health behavior as measured by the PhenX physical activity protocol

    Family support persons' health behavior will be measured in part by the PhenX comprehensive adult physical activity protocol questionnaire which assesses past-year frequency of physical activity. Scores range from 1 to 10 where higher scores indicate more intense usual physical activity.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  28. Health behavior as measured by the PhenX physical activity protocol

    Family support persons' health behavior will be measured in part by the PhenX comprehensive adult physical activity protocol questionnaire which assesses past-year frequency of physical activity. Scores range from 1 to 10 where higher scores indicate more intense usual physical activity.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  29. Health behavior as measured by the PhenX physical activity protocol

    Family support persons' health behavior will be measured in part by the PhenX comprehensive adult physical activity protocol questionnaire which assesses past-year frequency of physical activity. Scores range from 1 to 10 where higher scores indicate more intense usual physical activity.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  30. Health behavior as measured by the PhenX physical activity protocol

    Family support persons' health behavior will be measured in part by the PhenX comprehensive adult physical activity protocol questionnaire which assesses past-year frequency of physical activity. Scores range from 1 to 10 where higher scores indicate more intense usual physical activity.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

  31. Health behavior as measured by the PhenX medication adherence protocol

    Family support persons' health behavior will be measured in part by the PhenX adherence to medication regimen protocol questionnaire which assesses medication adherence and ability to refill prescriptions on schedule. Scores range from 12 to 48 where lower scores mean better adherence.

    Time frame: Baseline

  32. Health behavior as measured by the PhenX medication adherence protocol

    Family support persons' health behavior will be measured in part by the PhenX adherence to medication regimen protocol questionnaire which assesses medication adherence and ability to refill prescriptions on schedule. Scores range from 12 to 48 where lower scores mean better adherence.

    Time frame: Following session 3 (approx. 3 weeks after baseline)

  33. Health behavior as measured by the PhenX medication adherence protocol

    Family support persons' health behavior will be measured in part by the PhenX adherence to medication regimen protocol questionnaire which assesses medication adherence and ability to refill prescriptions on schedule. Scores range from 12 to 48 where lower scores mean better adherence.

    Time frame: Following session 4 (approx. 7-10 weeks after Baseline)

  34. Health behavior as measured by the PhenX medication adherence protocol

    Family support persons' health behavior will be measured in part by the PhenX adherence to medication regimen protocol questionnaire which assesses medication adherence and ability to refill prescriptions on schedule. Scores range from 12 to 48 where lower scores mean better adherence.

    Time frame: 1 month post-protocol (approximately 3 months after Baseline)

  35. Health behavior as measured by the PhenX medication adherence protocol

    Family support persons' health behavior will be measured in part by the PhenX adherence to medication regimen protocol questionnaire which assesses medication adherence and ability to refill prescriptions on schedule. Scores range from 12 to 48 where lower scores mean better adherence.

    Time frame: 6 months post-protocol (approximately 9 months after Baseline)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All direct respondent identifiers (e.g., names, EHR chart numbers) will be removed and maintained in a secure file for data linkage purposes, and will not be shared. Deidentification will be completed by the end of data processing, prior to the finalization of the public use data files. All other scientific data (survey data, EHR medical and blood pressure data) will be both preserved and shared, once deidentification is complete. A data dictionary which includes variable names, variable labels, question text as allowable, values, value labels, explanations of missing data, and scale-level descriptions and calculations, will also be shared.

Supporting information: Study protocol

Time frame: Datasets will be made available as soon as possible following study-associated publications documenting the study's outcomes. Datasets in the repository will be maintained for at least ten years.

Access criteria: Data and metadata will be shared through an open access repository (the online UT Southwestern Research Data Repository, part of the Texas Data Repository Dataverse). Data users will agree not to share or redistribute any data downloads. Data downloads (usage) will be tracked by the Repository. A Creative Commons copyright (CC0) is the default license used by the Texas Data Repository, which will support discoverability and use of the collection. The Repository also requires a Data Usage Agreement for downloaders, which creates an agreement between the downloader and owner of the data governing use of the data and related materials to be downloaded.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Apr 2031, 51 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 51 months is above that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Jan 18, 2027
Primary completionEst.
Apr 18, 2031
CompletionEst.
Apr 18, 2031
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
14 description edited
What changed in the outcomes
  • DescriptionBlood pressure control: how it is measured was reworded
  • DescriptionBlood pressure control#2: how it is measured was reworded
  • DescriptionBlood pressure control#3: how it is measured was reworded
  • DescriptionBlood pressure control#4: how it is measured was reworded
  • DescriptionBlood pressure control#5: how it is measured was reworded
  • DescriptionBlood pressure control#6: how it is measured was reworded
  • DescriptionBlood pressure control#7: how it is measured was reworded
  • DescriptionBlood pressure control#8: how it is measured was reworded
  • DescriptionBlood pressure control#9: how it is measured was reworded
  • DescriptionHypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE): how it is measured was reworded
  • DescriptionHypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#2: how it is measured was reworded
  • DescriptionHypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#3: how it is measured was reworded
  • DescriptionHypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#4: how it is measured was reworded
  • DescriptionHypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#5: how it is measured was reworded
Oct 16, 2026
Secondary outcomes
30 description edited, 10 more
What changed in the outcomes
  • DescriptionDyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index: how it is measured was reworded
  • DescriptionDyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index#2: how it is measured was reworded
  • DescriptionDyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index#3: how it is measured was reworded
  • DescriptionDyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index#4: how it is measured was reworded
  • DescriptionDyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index#5: how it is measured was reworded
  • DescriptionFamily relationship quality as measured by the FACES-IV Short Form: how it is measured was reworded
  • DescriptionFamily relationship quality as measured by the FACES-IV Short Form#2: how it is measured was reworded
  • DescriptionFamily relationship quality as measured by the FACES-IV Short Form#3: how it is measured was reworded
  • DescriptionFamily relationship quality as measured by the FACES-IV Short Form#4: how it is measured was reworded
  • DescriptionFamily relationship quality as measured by the FACES-IV Short Form#5: how it is measured was reworded
  • DescriptionFamily support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey: how it is measured was reworded
  • DescriptionFamily support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey#2: how it is measured was reworded
  • DescriptionFamily support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey#3: how it is measured was reworded
  • DescriptionFamily support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey#4: how it is measured was reworded
  • DescriptionFamily support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey#5: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE): how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#2: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#3: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#4: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#5: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the PhenX alcohol use protocol: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the PhenX alcohol use protocol#2: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the PhenX alcohol use protocol#3: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the PhenX alcohol use protocol#4: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the PhenX alcohol use protocol#5: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the PhenX medication adherence protocol: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the PhenX medication adherence protocol#2: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the PhenX medication adherence protocol#3: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the PhenX medication adherence protocol#4: how it is measured was reworded
  • Descriptionother outcomeHealth behavior as measured by the PhenX medication adherence protocol#5: how it is measured was reworded
  • …and 10 more, on the record history on ClinicalTrials.gov ↗
Oct 16, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Oct 16, 2026
    Primary outcomes 14 description edited
    What changed in the outcomes
    • DescriptionBlood pressure control: how it is measured was reworded
    • DescriptionBlood pressure control#2: how it is measured was reworded
    • DescriptionBlood pressure control#3: how it is measured was reworded
    • DescriptionBlood pressure control#4: how it is measured was reworded
    • DescriptionBlood pressure control#5: how it is measured was reworded
    • DescriptionBlood pressure control#6: how it is measured was reworded
    • DescriptionBlood pressure control#7: how it is measured was reworded
    • DescriptionBlood pressure control#8: how it is measured was reworded
    • DescriptionBlood pressure control#9: how it is measured was reworded
    • DescriptionHypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE): how it is measured was reworded
    • DescriptionHypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#2: how it is measured was reworded
    • DescriptionHypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#3: how it is measured was reworded
    • DescriptionHypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#4: how it is measured was reworded
    • DescriptionHypertension self-management behavior adherence as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#5: how it is measured was reworded
    Secondary outcomes 30 description edited, 10 more
    What changed in the outcomes
    • DescriptionDyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index: how it is measured was reworded
    • DescriptionDyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index#2: how it is measured was reworded
    • DescriptionDyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index#3: how it is measured was reworded
    • DescriptionDyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index#4: how it is measured was reworded
    • DescriptionDyadic relationship satisfaction as measured by the adapted Relationship Satisfaction Index#5: how it is measured was reworded
    • DescriptionFamily relationship quality as measured by the FACES-IV Short Form: how it is measured was reworded
    • DescriptionFamily relationship quality as measured by the FACES-IV Short Form#2: how it is measured was reworded
    • DescriptionFamily relationship quality as measured by the FACES-IV Short Form#3: how it is measured was reworded
    • DescriptionFamily relationship quality as measured by the FACES-IV Short Form#4: how it is measured was reworded
    • DescriptionFamily relationship quality as measured by the FACES-IV Short Form#5: how it is measured was reworded
    • DescriptionFamily support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey: how it is measured was reworded
    • DescriptionFamily support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey#2: how it is measured was reworded
    • DescriptionFamily support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey#3: how it is measured was reworded
    • DescriptionFamily support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey#4: how it is measured was reworded
    • DescriptionFamily support for hypertension self-management behavior as measured by the Chronic Illness Resources Survey#5: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE): how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#2: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#3: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#4: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the Hypertension Self-Care Activity Level Effects (H-SCALE)#5: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the PhenX alcohol use protocol: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the PhenX alcohol use protocol#2: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the PhenX alcohol use protocol#3: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the PhenX alcohol use protocol#4: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the PhenX alcohol use protocol#5: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the PhenX medication adherence protocol: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the PhenX medication adherence protocol#2: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the PhenX medication adherence protocol#3: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the PhenX medication adherence protocol#4: how it is measured was reworded
    • Descriptionother outcomeHealth behavior as measured by the PhenX medication adherence protocol#5: how it is measured was reworded
    • …and 10 more, on the record history on ClinicalTrials.gov ↗
    + 3 other changes: verification date, description and arm descriptions
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07849920
Responsible party
Sarah Woods (Principal Investigator, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Sep 30, 2026
Start date
Jan 18, 2027 (estimated)
Primary completion
Apr 18, 2031 (estimated)
Completion
Apr 18, 2031 (estimated)
Last update
Oct 16, 2026

Study contacts

Study Coordinator
Contact
WalkTogether@UTSouthwestern.edu
214-645-9532
Sarah Woods, PhD
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion